Evidence map›Paper›PMID 25775353›Full record

Observational studyJAMA neurology2015

Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.

Clifford R Jack, Heather J Wiste, Stephen D Weigand, David S Knopman, Prashanthi Vemuri, Michelle M Mielke, Val Lowe, Matthew L Senjem, Jeffrey L Gunter, Mary M Machulda and 4 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in JAMA neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed, 7 pooled it
26.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

235 citing papers in PubMed, 7 syntheses or guidelines pooled it, 390 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Age at menopause,Research square · 2026
    Article
  13. Article
  14. Sex differences in brain glucose metabolism and Alzheimer's disease risk and progression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Clifford R JackDepartment of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota.
Heather J WisteDepartment of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota.
Stephen D WeigandDepartment of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota.
David S KnopmanDepartment of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota.
Michelle M MielkeDepartment of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota.
Val LoweDepartment of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota.
Matthew L SenjemDepartment of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota.
Jeffrey L GunterDepartment of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic and Foundation, Rochester, Minnesota.
Brian E GreggDepartment of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota.
V Shane PankratzDepartment of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota.
Walter A RoccaDepartment of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota3Department of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota.
Ronald C PetersenDepartment of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota.
Mayo Clinic · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Mayo Clinic Interdisciplinary Women's Health Research ProgramK12HD065987 · NICHD · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL · 2010 to 2023
$6.7M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Sex-specific Risk for Vascular Dysfunction and Cognitive DeclineP50AG044170 · NIA · MAYO CLINIC ROCHESTER · PI MILLER, VIRGINIA M · 2012 to 2017
$6.1M
Aerobic Exercise in Alzheimer's Disease: Cognition and Hippocampal Volume EffectsR01AG043392 · NIA · UNIVERSITY OF MINNESOTA · PI YU, FANG · 2013 to 2018
$3.2M
Stroke and Cognitive Impairment in Aging Chronic Kidney Disease PatientsR01AG037551 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MURRAY, ANNE M · 2011 to 2015
$2.7M
Pathological basis of MRS and DTI changes in neurodegenerative dementiaR01AG040042 · NIA · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL · 2011 to 2015
$1.6M
Genome wide association study of gene expression levels in Alzheimer's diseaseR01AG032990 · NIA · MAYO CLINIC JACKSONVILLE · PI ERTEKIN-TANER, NILUFER · 2009 to 2011
$932k
NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG044170NIA NIH HHS R01 AG011378NIA NIH HHS R01-AG011378NIA NIH HHS R01 AG032990NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG037551NIA NIH HHS R01 AG040042NIA NIH HHS R01 AG041851NIA NIH HHS R01-AG041851NIA NIH HHS R01 AG043392NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904NIA NIH HHS U01-AG06786NICHD NIH HHS K12 HD065987
6 · The paper itself

Abstract

importanceTypical cognitive aging may be defined as age-associated changes in cognitive performance in individuals who remain free of dementia. Ideally, the full adult age spectrum should be included to assess brain imaging findings associated with typical aging.

objectiveTo compare age, sex, and APOE ε4 effects on memory, brain structure (adjusted hippocampal volume [HVa]), and amyloid positron emission tomography (PET) in cognitively normal individuals aged 30 to 95 years old. DESIGN, SETTING, AND

participantsCross-sectional observational study (March 2006 to October 2014) at an academic medical center. We studied 1246 cognitively normal individuals, including 1209 participants aged 50 to 95 years old enrolled in a population-based study of cognitive aging and 37 self-selected volunteers aged 30 to 49 years old. MAIN OUTCOMES AND MEASURES: Memory, HVa, and amyloid PET.

resultsOverall, memory worsened from age 30 years through the 90s. The HVa worsened gradually from age 30 years to the mid-60s and more steeply beyond that age. The median amyloid PET was low until age 70 years and increased thereafter. Memory was worse in men than in women overall (P < .001) and more specifically beyond age 40 years. The HVa was lower in men than in women overall (P < .001) and more specifically beyond age 60 years. There was no sex difference in amyloid PET at any age. Within each sex, memory performance and HVa were not different by APOE ε4 status at any age. From age 70 years onward, APOE ε4 carriers had significantly greater median amyloid PET than noncarriers. However, the ages at which 10% of the population were amyloid PET positive were 57 years for APOE ε4 carriers and 64 years for noncarriers. CONCLUSIONS AND RELEVANCE: Male sex is associated with worse memory and HVa among cognitively normal individuals, while APOE ε4 is not. In contrast, APOE ε4 is associated with greater amyloid PET (from age 70 years onward), while sex is not. Worsening memory and HVa occur at earlier ages than abnormal amyloid PET. Therefore, neuropathological processes other than β-amyloidosis must underlie declines in brain structure and memory function in middle age. Our findings are consistent with a model of late-onset Alzheimer disease in which β-amyloidosis arises in later life on a background of preexisting structural and cognitive decline that is associated with aging and not with β-amyloid deposits.

Indexed as

AdultAgedAged, 80 and overAge FactorsAgingAmyloid beta-PeptidesApolipoprotein E4BrainCross-Sectional StudiesFemaleHippocampusHumansMaleMemoryMiddle AgedPositron-Emission TomographyAmyloid beta-PeptidesApolipoprotein E4

Identifiers

PMID25775353
PMCPMC4428984
OpenAlexW2104287008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.